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lel sample (n = 137) the average quarterly costs had increased by
13% (ns). CONCLUSIONS: Computerised data collection per-
formed by the doctor provide detailed information about diag-
nosis, treatments, and referrals making possible the study of
patient pathways and costs. DPMA is cost-effective in provision
of care.
ASTHMA
ASTHMA—Methods and Concepts
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A COMPARISON OF TWO APPROACHES TO ESTIMATE
ANNUAL MEDICATION COSTS IN THE KORA ASTHMA AND
ALLERGY STUDY
Holle R, Stark R, Behrend C, John J
GSF—Research Centre for Environment and Health, Neuherberg,
Germany
OBJECTIVES: Comparison of annual medication costs in a 
population-based study using a prediction formula based on 7
day medication history to cost data provided by health insurance
companies. METHODS: The KORA Asthma and Allergy 
study evaluated cost of illness due to asthma and allergies in a
population-based case-control design. Medication costs origi-
nated from a 7 day medication history (interview) and from
health insurance data. Drugs documented per interview were
assigned an average price per deﬁned daily dose (DDD) for each
standard package size group. Weekly medication costs were
extrapolated by multiplying price per DDD (medium package
size) by predicted length of intake according to general ATC
group. For consenting subjects, all medications reimbursed by
the health insurance companies for 1998 were obtained. The
annual total costs as well as cost differences between disease
groups were compared between both approaches. RESULTS: Of
1534 subjects participating in the KORA study, 1249 were
insured publicly and 63.8% of those consented to release their
health insurance data. Of 614 persons with prescribed medica-
tions according to insurance data, 233 (38%) reported no pre-
scribed medications during the interview. Median (inter-quartile
range) annual costs for this group were 37€ (16–103€). For the
other 381 subjects (62%), annual insurance costs were 260€
(116–638€) whereas predicted costs were higher (364€; 104–
863€). For subjects with asthma or allergy, predicted costs agreed
better with annual costs. Costs extrapolated from interview data
correlated signiﬁcantly (r = 0.63) with the annual costs. CON-
CLUSIONS: Estimation of annual medication costs for chronic
disease patients from seven day medication history data is feasi-
ble and estimates of group averages are similar to full annual
data from health insurance companies. For population-based
samples the latter approach is logistically more difﬁcult, is less
accepted by subjects, and does not encompass costs of most of
OTC drugs.
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COST ESTIMATION IN CLINICAL PIGGY-BACK STUDIES WITH
DISCONTINUATIONS—COMPARISON OF DIFFERENT
APPROACHES
Svensson K
AstraZeneca R&D, Lund, Sweden
OBJECTIVES: Estimating costs for different pharmaceutical
treatments based on data from clinical studies with discontinu-
ation is a problem with no general solution. Especially early dis-
continuations are often correlated with high initial costs, which
may have large impact on the estimates. A number of approaches
suggested in the literature for dealing with this problem were
investigated using data from clinical studies in the respiratory
ﬁeld to see if a consistent pattern could be found. METHODS:
Data from three large clinical studies (two concerning asthma,
one concerning COPD) were investigated for three different
approaches: PYA, Patient-Year Approach (linear extrapolation
for each patient to nominal duration of study), GMI, Group
Mean Imputation where missing data for a certain period is
replaced by the relevant group mean for corresponding period,
and GSA, Group-Sum Approach where data are summed over
treatment groups, implying that data are weighted according to
time in study for each patient. While the ﬁrst two approaches
are based on individual data and variation in estimates are easily
found by standard methods, precision in GSA estimates is found
by non-parametric bootstrapping. RESULTS: Data show that
discontinuations, and especially early discontinuations due to
exacerbations followed by intensive treatment, can have a sub-
stantial impact on the PYA approach, where the estimated mean
cost can be twice as high compared to the other approaches.
Demanding a certain time in study as qualifying for inclusion in
the analysis will gradually bring the results in agreement with
the GMI and GSA approach. CONCLUSIONS: In large clinical
studies, the GMI approach may be inconvenient because of
varying periods. The GSA approach in combination with non-
parametric bootstrapping for ﬁnding precision in estimates is a
simple and robust method.
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FROM SF-36 TO UTILITY SCORES: A COMPARISON OF
DIFFERENT ALGORITHMS IN DIFFERENT SETTINGS
Svensson K
AstraZeneca R&D, Lund, Sweden
OBJECTIVES: To investigate if the results of four published
algorithms for calculating utility values from assessments of SF-
36 are in agreement with the responses of traditional efﬁcacy
variables assessed in clinical studies in the respiratory ﬁeld.
METHODS: Data from six different randomized clinical studies,
two from each of the disease areas of asthma, rhinitis and COPD,
comparing two treatments, are used in the investigation. Base-
line values before randomizing to study treatment are compared
for the algorithms as well as change during treatment. Change
during treatment is compared to the primary efﬁcacy variable in
each study. RESULTS: Mean utility values at baseline show a
consistent pattern across disease areas with large individual vari-
ation, with utility values ranging from 0.28 to 0.99 and with
mean values ranging from 0.58 to 0.82. Change during treat-
ment is small (0.00 to 0.11) and in most cases statistically non-
signiﬁcant when comparing treatments. Correlation with clinical
efﬁcacy is of moderate magnitude. CONCLUSION: The two
utility measures based on Standard Gamble or TTO seems to be
slightly better than those based on VAS or linear regression. The
pattern across the different disease areas is consistent for the dif-
ferent algorithms.
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OBJECTIVE: To estimate aggregate burden imposed on the 
Australian community each year by the systemic rheumatic dis-
order ankylosing spondylitis (AS). METHODS: The study used
a bottom-up approach consisting of: a survey of 143 AS patients;
estimation of the costs associated with each patient; estimation
of the incidence and prevalence of AS in Australia; and integra-
tion of these data to estimate the total costs of AS in Australia
each year. The patient survey collected information about
respondents’ disease characteristics, quality of life, health care
resource utilisation, and employment. Health Care costs accrued
by patients were classiﬁed into six categories: medications; 
hospitalisations; specialist attendances; visits to other medical
professionals and allied health care appointments; medical pro-
cedures and tests; and complementary Health Care appoint-
ments. Non-Health Care costs comprised lost productivity due
to absence from paid and unpaid employment, assessed using the
human capital and friction cost methods, and using the value of
a quality-adjusted life year (QALY). RESULTS: It is estimated
the number of patients in the Australian health care system with
diagnosed AS is currently 6895. However, an additional 12,805
un- or misdiagnosed AS patients are predicted. The aggregate
annual costs of AS in Australia in 2004 are estimated to be
between AUS$109,432,035 and AUS$483,010,549, depending
on methods used to assess indirect costs. Direct Health Care
costs of AS are expected to be approximately A$34 million in
2004, accounting for 7%–31% of the total burden. CONCLU-
SIONS: Comparison of the aggregate costs of AS with other cost-
of-illness studies reported in Australia shows that the health care
costs of AS are lower than those for many other conditions.
However, the majority of the total costs of AS is attributable to
lost productivity highlighting the effect on a predominantly
working-age population. The burden of AS in Australia is
expected to increase in the next four years as population grows.
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OBJECTIVE: To evaluate the cost-effectiveness and the total cost
differences between valdecoxib 10 or 20mgqd and diclofenac 
75mg SR bid in the treatment of OA of the knee and/or hip.
METHODS: Study 063, a double-blind, randomized, 12-month
study, evaluated the efﬁcacy of valdecoxib 10mgqd (n = 259)
and valdecoxib 20mgqd (n = 261) versus diclofenac 75mg SR
bid (n = 262). Hospitalizations, unscheduled health care visits,
concomitant medications and unscheduled diagnostic and
medical procedures were prospectively collected during the trial.
This economic evaluation was conducted from a UK National
Health Service perspective, using published UK sources for cost.
Cost per averted ulcer was used as a cost-effectiveness measure.
RESULTS: Valdecoxib 10 and 20mgqd had comparable efﬁcacy
to diclofenac 75mg SR bid at all time points; none of the 95%
conﬁdence intervals (CIs) overlapped 15mm VAS, the smallest
difference determined to be clinically meaningful. The overall
incidence of adverse events was signiﬁcantly lower in both valde-
coxib groups than in the diclofenac group. Both valdecoxib
groups demonstrated a lower mean number of hospital days
(valdecoxib 10: 0.44 days; valdecoxib 20: 0.53 days; diclofenac:
1.02 days) and a smaller percentage of patients hospitalized
(valdecoxib 10: 7.3%; valdecoxib 20: 8.4%; diclofenac: 9.5%).
The valdecoxib 10mg group resulted in lower mean total costs
than the diclofenac group with a treatment cost difference of—
£129.20 (95% CI: -£448.80, £190.39). The corresponding dif-
ference between the valdecoxib 20mg group and the diclofenac
group was -£79.74 (95% CI: -£400.92, £241.44). Cost per
averted ulcer showed valdecoxib as the dominant therapy with
fewer ulcers and lower total medical costs. CONCLUSIONS:
Valdecoxib 10 and 20mgqd provided comparable efﬁcacy with
a more beneﬁcial safety proﬁle at a similar total medical cost
compared to diclofenac 75mg bid in treating OA.
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OBJECTIVE: To evaluate the determinants of costs and quality
of life for patients in Australia with the systemic rheumatic 
disorder ankylosing spondylitis (AS). METHODS: The study
employed a survey of 143 AS patients in Australia to collect
information about respondents’ disease history, quality of life,
health care resource utilisation and employment. Patient-level
estimation of total (direct and indirect) costs was performed.
Two disease status instruments measured disease activity and
level of disability: Bath Ankylosing Spondylitis Function Index
(BASFI) and Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI). The burden of AS on quality of life was assessed using
utility values derived by the Assessment of Quality of Life
(AQoL) scale. RESULTS: The mean utility value across the sur-
veyed population was 0.56. Utilities ranged from 0.02 to 1.00,
with a median of 0.58 and a mode of 0.84. Mean BASFI and
BASDAI scores were 4.1 and 4.8, respectively. The mean cost per
patient over the 3 months prior to the survey was estimated to
be between AUS$2188 and AUS$6870 depending on the method
used to value indirect costs. Linear regression showed signiﬁcant
associations between utility values and BASFI and BASDAI
scores. Log-linear regression of Health Care and indirect costs
against respondents’ BASFI and BASDAI scores showed a sig-
niﬁcant association when each of these instruments is used to
predict health care costs. Log-linear regression of total costs also
showed that these increased with disease severity. CONCLU-
SIONS: BASFI and BASDAI scores compared with utility values
show an intuitive relationship: as disease severity decreases,
utility scores increase. Similarly, total costs are positively related
to disease severity. This study showed the costs and quality of
life effects of AS can be predicted by patients’ disease severity.
Knowledge of the predictors of costs enable policies and/or
health care interventions to be adopted that help to minimise
these costs.
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OBJECTIVES: We performed a macro-economic assessment of
the cost of osteoarthritis in 2002 and compared our results to
those computed in 1991 in an earlier study using the same
methodology. METHODS: The macro-economic cost assessment
was based on prevalence data. Medical consumption items were
described both in term of quantity and price. Data were collected
